soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 PDF) and in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the Randomized Oral Semaglutide: Impact on Cardiovascular

The approval came as a consequence of the findings of phase 3a research published in the New England Journal of Medicine

GLP-1 medications accounted for 5.4% of all American adult prescriptions in September 2024, up from 3.5% in 2023

Copper ions can catalyze oxidation reactions, which means formulation matters enormously

Stop using Saxenda and get medical help right away if you have any symptoms of a serious allergic reaction including swelling of your face, lips, tongue, or throat, fainting or feeling dizzy, very rapid heartbeat, problems breathing or swallowing, or severe rash or itching depression or thoughts of suicide

Miller JC